Trial Profile
An Open Label Study of Apremilast in Chronic Idiopathic Pruritus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- 08 Apr 2020 Status changed from active, no longer recruiting to completed.
- 03 Sep 2019 Planned End Date changed from 31 Jul 2019 to 31 Dec 2019.
- 03 Sep 2019 Planned primary completion date changed from 31 Jul 2019 to 31 Dec 2019.